This article has been updated from a previous version, which incorrectly described Innogenetics as a Dutch company.
VANCOUVER, March 27 (GenomeWeb News) - Innogenetics, a Belgian diagnostics company, will begin offering human leukocyte antigen typing on PamGene's microarray platform later this year, according to a PamGene scientific advisory board member.
Bertrand Jordan, who sits on PamGene's SAB, told GenomeWeb Daily News sister publication BioArray News at the World Microarray Congress here on Friday that Innogenetics is using a system specifically designed for its use called the PamStation 12 to introduce the HLA typing.
The companies began collaborating on the development of the PamStation 12 in May 2004.
Innogenetics does not have exclusive rights to the PS-12, however. "PamGene will be able to sell PS-12 outside of Innogenetics,"
"Array diagnostics still have some difficulty getting into the marketplace due to a lot of competition from RT-PCR," he said. He added that PamGene's 3D array technology is not yet "mainstream" due to "a lack of high-profile collaborations and papers."